Skip to content

Outcomes and Policy Research

Gatwood

Description

Dr. Gatwood’s overarching focus is on improving medication adherence and health outcomes associated with chronic disease. His work approaches this from two distinct yet related methods: 1) identifying populations with poor medication use and determining the factors related to nonadherence using database analyses; and 2) developing and testing technology-focused behavioral interventions aimed at improving medication use and other health-related behaviors. While at UTHSC, this has included analyzing veterans’ antidiabetic medication use patterns for racial and regional variation in adherence and outcomes, testing the effectiveness of tailored text messages to improve diabetes self-care activities among underserved African American adults with diabetes, using real-time mobile monitoring to improve glaucoma medication adherence, determining the impact of clinical pharmacy services on medication use and short-term health outcomes, and, most recently, examining oral anticancer medication adherence and its initiation on adherence to other chronic disease medications.

Dr. Gatwood can be reached at jgatwood@utshc.edu or 615-532-3403.
Members and Collaborators

Dr. Csaba Kovesdy, UTHSC College of Medicine (Nephrology) and Memphis VA Medical Center

Dr. Jim Bailey, UTHSC College of Medicine (Internal Medicine)
Projects
  • Improving Self-Care Decisions of Medically Underserved African-Americans with Uncontrolled Diabetes: Effectiveness of Patient-Driven Text Messaging versus Health Coaching (PI: Jim Bailey; PCORI Project Program Award SC15-1503-28336)
  • The influence of race on medication adherence and health outcomes in veterans with diabetes (UTHSC iRISE KL2) 
  • Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma (ClinicalTrials.gov: NCT03194828)
Selected Publications
  1. Gatwood J, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, Kovesdy CP. Disparities in Initial Oral Antidiabetic Medication Adherence among Veterans with Incident Diabetes.  J Manag Care Spec Pharm (in press)
  2. Gatwood J, Johnson J, Jerkins B. Adherence to topical glaucoma medication: Comparing a new wireless device and self-reported measures. J Glaucoma (in press)
  3. Gatwood J, Hohmeier KC, Farr G, Eckel SF. A Comparison of Approaches to Student Pharmacist Business Planning in Pharmacy Practice Management. Am J Pharm Educ (epub ahead of print). Article ajpe6279
  4. Gatwood J, Gatwood K, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: A review. Am J Health Syst Pharm 2017; 74(19): 1549-1557. 
  5. Gatwood J, Balkrishnan R, Erickson SR, An LC, Piette JD, Farris KB. The impact of tailored text messages on health beliefs and medication adherence in adults with diabetes: A randomized pilot study. Res Soc Adm Pharm 2016; 12(1): 130-140. PubMed PMID: 25980582.

 

Wang

Description
Junling Wang, PhD, is a Professor in Health Outcomes and Policy Research at the University of Tennessee Health Science Center, College of Pharmacy. She received her PhD in Pharmaceutical Health Services Research from the University of Maryland in 2005. Dr. Wang has continuously concentrated on the following two research areas: (1) outcomes/economic evaluation of pharmaceutical products and services including medication therapy management; and (2) racial and ethnic disparities in the utilization of health services and prescription drugs. Her research has been funded by the National Institutes of Health (NIH)/National Institute on Aging, Pharmacy Quality Alliance, Pharmaceutical Research and Manufacturers of America Foundation, American Association of Colleges of Pharmacy, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly and Company, and the State of Tennessee. Dr. Wang has published over 50 research articles in peer-reviewed journals. Her work has been cited by the Federal government as reasons for federal policy reform for the Medicare eligibility criteria for medication therapy management services. She has also received recognition for her research including the Nobuo Meade International Research Award and an Honorable Mention for Betty J. Cleckley Minority Issues Research Award from the American Public Health Association (APHA) Aging and Public Health Section. Dr. Wang’s leadership roles have included the APHA Aging and Public Health Section Program Chair, Membership Chair, governing councilor, and Nominations Committee.
Lab Personnel
Research Assistant: Yanru Qiao, MS
Projects
  • “Finding Effective and Equitable MTM Eligibility Criteria.” Source: NIA/NIH. 08/2015-03/2018. $987,562. Role: Principal Investigator.
  • “Impact of Adalimumab Initiation on Co-Therapies and Associated Adverse Effects and Health Services Utilization among Patients with Rheumatoid Arthritis.” Source: AbbVie. 07/01/2017-02/28/2018. Role: Principal Investigator. 
  • “Steroids Utilization and Initiation of Biologic Disease-Modifying Antirheumatic Drugs among Patients with Rheumatoid Arthritis.” Source: AbbVie. 09/2016-04/2017. $98,286. Role: Principal Investigator. 
  • “Patterns of Medication Utilization among Patients with Multiple Chronic Conditions.” Source: Pharmaceutical Research and Manufacturers of America. 11/01/2015-12/31/2017. $60,000. Role: Principal Investigator. 
  • "A Historical Cohort Study on Discontinuation/Interruption of Warfarin Therapy and Outcomes in Patients with Atrial Fibrillation." Source: Pfizer Inc. 07/01/2013-12/31/2015. $204,840. Role: Principal Investigator. 
  • “Health Implications of MTM Eligibility Criteria.” Source: NIA/NIH. 09/2011-06/2015. $892,698. Role: Principal Investigator.
  • “Evaluation of the Effect of Telephonic Medication Therapy Management Services to Medicare Part D Patients on Medication Adherence, Quality and Health Care expenditures (T-MAQ study).” Source: Pharmacy Quality Alliance. 10/10-04/12. $240,000. Role: Co-Principal Investigator (35%).
  •  “Disparity Implications of the Eligibility Criteria for Medication Therapy Management Services.” Source: Pharmaceutical Research and Manufacturers of America Foundation Research Starter Grant in Health Outcomes. 02/09-01/12. $60,000. Role: Principal Investigator.
  • “The Development, Implementation, and Evaluation of a Pharmacy-Based Collaborative Diabetes Management Program.” Source: Roche Diagnostics. 07/07-07/12. $368,460. Role: Co-Investigator ($10,000 or 125 hours effort). Principal Investigator: Kam Nola. 
  • “Duloxetine in the Treatment of Patients with Major Depressive Disorder Comorbid with Chronic Pain.” Source: Eli Lilly and Company. 07/09-12/09. $96,156. Role: Principal Investigator.
  •  “Pharmacists’ Acceptable Levels of Compensation for Medication Therapy Management Services.” Source: American Association of Colleges of Pharmacy New Investigators Program for Pharmacy Faculty. 12/07-12/09. $10,000. Role: Principal Investigator. 
  • “The Effect of Pharmacist Intervention on the Use of Zostavax®  in a Community Pharmacy Setting.” Source: Investigator Initiated Studies Program, Merck & Co. and American Pharmacists Association Foundation Incentive Grant for Practitioner Innovation in Pharmaceutical Care. 01/08-04/09. $18,342. Role: Co-Investigator ($5,000 or 40 hours effort). Principal Investigator: Lindsay J. Ford.
  • “Economic Evaluation of Psychiatric Medication Use in Tennessee among TennCare Pediatric Enrollees.” Source: Bureau of TennCare, Department of Finance and Administration, State of Tennessee. 03/06-08/07. $313,460. Role: Co-Principal Investigator (15% effort). Principal Investigator: Dick R. Gourley.
  • “Preference Based Valuation of Resource Variation in Medication Therapy Management Services.” Source: Pharmaceutical Research and Manufacturers of America Foundation. 01/07-12/08. $60,000. Role: Co-Investigator (5% effort in-kind).  Principal Investigator: Song Hee Hong. 
  • “A Comparison of Direct Medical Costs across Racial and Ethnic Groups among Children with Cancer.” Source: University of Tennessee College of Pharmacy Faculty Seed Grant Award 11/06-06/07. $9,398. Role: Principal Investigator (20% effort in-kind). 
  •  “The Economic Implications of Racial and Ethnic Disparities in the Use of Selective Serotonin Reuptake Inhibitors.” Source: University of Tennessee College of Pharmacy Faculty Seed Grant Award. 11/05-06/06. $5,500. Role: Principal Investigator (20% effort in-kind).
Selected Publications
  1. Lu D, Qiao Y, Brown NE, Wang J. Racial and ethnic disparities in influenza vaccination among adults with chronic medical conditions vary by age in the United States. PLoS One. 2017 Jan 12;12(1):e0169679. doi: 10.1371/journal.pone.0169679.
  2. Tang J, Kaddis A, Bailey J, Chang C, Faris R, Hong SH, Levin M, Wang J. Effects of specialty pharmacy care on health outcomes in multiple sclerosis. American Health & Drug Benefits. 2016;9(8):420-429.
  3. Jamison JJ, Wang J, Surbhi S, Adams S, Solomon D, Hohmeier KC, McDonough S, Eoff JC 3rd. Impact of Medicare Part D on racial and ethnic minorities. Diversity and Equality in Health Care. 2016;13(5):326-333.
  4. Hohmeier KC, McDonough SL, Wang J. Co-creation of market expansion in point-of-care testing in the United States: Industry leadership perspectives on the community pharmacy segment. Research in Social & Administrative Pharmacy. 2016 Oct 27. pii: S1551-7411(16)30236-4. doi: 10.1016/j.sapharm.2016.09.008. [Epub ahead of print]
  5. Lu D, Qiao Y, Johnson KC, Wang J. Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma. Journal of Asthma. 2016 Sep 27:1-10. doi: 10.1080/02770903.2016.1238927. [Epub ahead of print]
  6. Wang J, Qiao Y, Spivey C, Li C, Clark C, Deng Y, Liu F, Tillman J, Chisholm-Burns M. Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. Journal of Pharmaceutical Health Services Research. 2016;7(4):209-215. doi: 10.1111/jphs.12142.
  7. Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsatter Y, Chakrabarti A, Wang J. Economic outcomes of warfarin discontinuation among patients with atrial fibrillation. American Journal of Pharmacy Benefit. 2016;8(4):141-148. 
  8. Bess DT, Taylor J, Schwab CA, Wang J, Carter J. An innovative approach to pharmacy law education utilizing a mock board of pharmacy meeting. Innovations in Pharmacy. 2016;7(1):Article 9.
  9. Wang J, Qiao Y, Shih YC, Jarrett-Jamison J, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. Journal of Managed Care & Specialty Pharmacy. 2015;21(11):993-1003.
  10. Bell TM, Wang J, Nolly R, Ozdenerol E, Relyea G, Zarzaur BL. Predictors of functional limitation trajectories after injury in a nationally representative U.S. older adult population.Annals of Epidemiology. 2015;25(12):894-900. doi: 10.1016/j.annepidem.2015.08.012.
  11. Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, Masseria C, Kachroo S, Abdulsattar Y, Wang J. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research & Opinion. 2015; Sep 21:1-9. [Epub ahead of print]
  12. Wang J, Shih Y-CT, Qin Y, Young T, Spivey CA, Thomas Z, Solomon D, Chisholm-Burns M. Trends in Medicare Part D medication therapy management eligibility criteria. American Health and Drug Benefits. 2015;8(5):247-255.
  13. Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsatter Y, Chakrabarti A, Wang J. Discontinuation/interruption of warfarin therapy in patients with non-valvular atrial fibrillation. Journal of Managed Care & Specialty Pharmacy. 2015;21(7):596-606. 
  14. Wang J, Zhang Z, Spivey CA, Chisholm-Burns M. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria in Non-Medicare Population. Research in Social and Administrative Pharmacy. 2014;10(6):904–917.
  15. Wang J, Qiao Y, Shih YC, Jamison JJ, Spivey CA, Li L, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA. Effects of Medicare Part D on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits. 2014;7(6):346-358.
  16. Wang J, Qiao Y, Shih YC, Dagogo-Jack S, Spivey CA, Wan JY, White-Means SI, Cushman WC, Chisholm-Burns MA. Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of Pharmaceutical Health Services Research.2014;5(2):109-118.              
  17. Wang J, Surbhi S, Kuhle J. Receipt of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers among Medicare beneficiaries with diabetes and hypertension. Journal of Pharmaceutical Health Services Research. 2014;5(1):67-74.
  18. Wang J, Munshi K, Hong SH. Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents. Research in Social and Administrative Pharmacy. 2014;10(1):126-140.
  19. Wang J, Qiao Y, Shih YC, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Research in Social and Administrative Pharmacy. 2014;10(1):106-125. 
  20. Wang J, Qiao Y. Historical trend of disparity implications of Medicare MTM eligibility criteria. Research in Social & Administrative Pharmacy. 2013;9(6):758-769.
  21. Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed dose combination antihypertensive drug therapy. American Journal of Hypertension. 2013;26(7):879-887.
  22. Munshi KD, Shih YC, Brown LM, Dagogo-Jack S, Wan JY, Wang J. Disparity implications of the Medicare MTM eligibility criteria: a literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2013;13(2):201-216.
  23. Hong SH, Wang J, Tak S. A patient-centric goal in time to blood pressure control from drug therapy initiation. Clinical & Translational Science. 2013;6(1):7-12.
  24. Wang J, Ford LJ, Wingate L, Frank SK, Jaber NH, Randolph R, Smith CT, Lane S, Foster SL. The effect of pharmacist intervention on the use of herpes zoster vaccine in a community pharmacy setting. Journal of the American Pharmacists Association. 2013;53(1):46-53.
  25. Wang J, Brown LM, Hong SH. Racial and ethnic disparities in meeting MTM eligibility criteria among the non-Medicare Population. Journal of the American Pharmacists Association. 2012;52(5):e87-96.
  26. Wang J, Hong SH. Contingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services. Research in Social & Administrative Pharmacy. 2012 March 19. [Epub ahead of print]
  27. Ganguli A, Wang J, Gourley DR. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Research in Social & Administrative Pharmacy. 2012;8(2):157-65.  
  28. Hong SH, Liu J, Wang J, Brown LM, White-Means SI. A conjoint analysis of patient preferences on Medicare medication therapy management. Journal of the American Pharmacists Association. 2011;51(3):378-387. 
  29. Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research & Opinion. 2011;27(7):1303-13.
  30. Wang J, Hong SH, Brown LM, Meng S. Pharmacists’ acceptable levels of compensation for MTM services: a conjoint analysis. Research in Social & Administrative Pharmacy. 2011;7(4):383-395.
  31. Wang J, Thomas J, Byrd D, Nola K, Liu J. Status of diabetes care among community pharmacy users with diabetes: an analysis of the Medical Expenditure Panel Survey. Journal of the American Pharmacists Association. 2010;50(4):478-484.
  32. Wang J, Mullins CD, Brown LM, Shih YC, Dagogo-Jack S, Hong SH, Cushman WC. Disparity implications of Medicare eligibility criteria for medication therapy management services.Health Services Research. 2010;45(4):1061-1082.
  33. Wang J, Mullins CD, Chang CF, Gourley DR, Shih YC, Dagogo-Jack S, Cushman WC. Comparison of changes over time in per capita health expenditures across racial and ethnic groups. International Journal of Public Policy. 2010;6(3/4):172-189. 
  34. Mullins CD, Seal B, S neoane-Vazquez E, Sankaranrayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good research practice for measuring drug costs in cost-effectiveness: Medicare, Medicaid, and other US government payers perspectives: the ISPOR Drug Cost Task Force Report-Part IV. Value in Health. 2010;13(1):18-24.
  35. Saalfrank MA, Wang J, Brown LM. Racial and ethnic differences in health states and the implications for cost utility analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2009:9(4):365-373.
  36. Wang J, Mullins CD, Zuckerman IH, Walker GD, Suda KJ, Yang Y, White-Means SI. Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. Research in Social & Administrative Pharmacy. 2008;4(3):206-17.
  37. Wang J, Dong Z, Hong SH, Suda KJ. A comparison of direct medical costs across racial and ethnic groups among children with cancer. Current Medical Research & Opinion. 2008;24(3):847-58.
  38. Wang J, Miller N, Hufstader MA, Bian Y. The health status of Asian Americans and Pacific Islanders and their access to health services. Social Work in Public Health. 2008;23(1):15-43.
  39. Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing new prescription drugs: disparities among non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Health Services Research. 2007;42(4):1499-519.
  40. Wang J, White-Means SI, Hufstader MA, Walker GD. The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. Current Medical Research & Opinion. 2007;23(4):853-63.
  41. Wang J, Saalfrank MA, Hong SH, Liu C, Gourley DR. Patterns of reporting health-related quality of life across racial and ethnic groups. Expert Review of Pharmacoeconomics & Outcomes Research. 2007;7(2):177-86.
  42. Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in access to essential new prescription drugs between non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Medical Care Research & Review. 2006;63(6):742-63.
  43. Mullins CD, Shaya FT, Meng F, Wang J, Bron MS. Comparison of first refill rates among branded SSRI users. Clinical Therapeutics. 2006;28(2):297-305. 
  44. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005;25(5):660-7. 
  45. Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet C. Economic disparities in treatment costs among ambulatory Medicaid cancer patients. Journal of the National Medical Association. 2004;96(12):1565-74.
  46. Zuckerman IH, Weiss SR, McNally D, Layne B, Mullins CD, Wang J. Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. The American Journal of Managed Care. 2004;10(7):493-500.
  47. Mullins CD, Cooke JL, Wang J, Shaya FT, Hsu VD, Brooks S. Disparities in prevalence rates for lung, colorectal, breast and prostate cancers in Medicaid. Journal of the National Medical Association. 2004;96(6):809-16.
  48. Mullins CD, Wang J, Cooke JL, Blatt L, Baquet CR. Longitudinal versus cross-sectional methodology for estimating the economic burden of breast cancer: a pilot study. Pharmacoeconomics. 2004;22(5):285-91.
  49. Mullins CD, Wang J, Stoller J. Major components of the direct medical costs of a1-antitrypsin deficiency. Chest. 2003;124(3):826-31.
  50. Mullins CD, Blatt L, Wang J. Societal implications of the pharmacoeconomics of a1-antitrypsin deficiency. Expert Review of Pharmacoeconomics & Outcomes Research. 2002; 2(3):243-9. 
  51. Mullins CD, Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Pharmacoeconomics. 2002;20(1):9-21.
  52. Mullins CD, Wang J, Palumbo FB, Stuart B. The impact of pipeline drugs on drug spending growth. Health Affairs. 2001;20(5):210-5.

Last Published: Nov 7, 2017